BidaskClub lowered shares of Enzymotec (NASDAQ:ENZY) from a hold rating to a sell rating in a research note published on Saturday morning.
A number of other research firms have also recently issued reports on ENZY. Wells Fargo & Co upped their price objective on Enzymotec from $9.50 to $12.00 and gave the stock a market perform rating in a report on Monday, October 30th. Jefferies Group reiterated a hold rating and issued a $11.50 price objective on shares of Enzymotec in a report on Thursday, October 19th. Finally, Zacks Investment Research upgraded Enzymotec from a strong sell rating to a hold rating in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The company presently has an average rating of Hold and a consensus price target of $11.75.
Enzymotec (ENZY) opened at $11.88 on Friday. Enzymotec has a fifty-two week low of $6.30 and a fifty-two week high of $12.35. The stock has a market capitalization of $278.21, a PE ratio of -44.00, a PEG ratio of 3.19 and a beta of 1.22.
ILLEGAL ACTIVITY NOTICE: “Enzymotec (ENZY) Downgraded by BidaskClub to “Sell”” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.com-unik.info/2018/01/10/enzymotec-enzy-downgraded-by-bidaskclub-to-sell.html.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.